CYP19A1 and breast carcinoma: About 70% of all breast cancers are estrogen receptor positive (ER+) and are treated with antiestrogens such as Tamoxifen (selective estrogen receptor modulator; SERM), Faslodex/fulvestrant/ICI182,780 (selective estrogen receptor downregulator; SERD) or aromatase inhibitors (AI).